116 related articles for article (PubMed ID: 10193822)
1. Pharmacokinetics of clodronate in haemodialysis patients.
Ala-Houhala I; Saha H; Liukko-Sipi S; Ylitalo P; Pasternack A
Nephrol Dial Transplant; 1999 Mar; 14(3):699-705. PubMed ID: 10193822
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of clodronate in peritoneal dialysis patients.
Saha HH; Ala-Houhala IO; Liukko-Sipi SH; Ylitalo P; Pasternack AI
Perit Dial Int; 1998; 18(2):204-9. PubMed ID: 9576370
[TBL] [Abstract][Full Text] [Related]
3. Skeletal deposition of clodronate is related to parathyroid function and bone turnover in dialysis patients.
Saha H; Ala-Houhala I; Ylitalo P; Kleimola T; Pasternack A
Clin Nephrol; 2002 Jul; 58(1):47-53. PubMed ID: 12141406
[TBL] [Abstract][Full Text] [Related]
4. Removal of clodronate by haemodialysis in end-stage renal disease patients.
Beigel AE; Rienhoff E; Olbricht CJ
Nephrol Dial Transplant; 1995 Dec; 10(12):2266-8. PubMed ID: 8808223
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of clodronate in renal failure.
Saha H; Castren-Kortekangas P; Ojanen S; Juhakoski A; Tuominen J; Tokola O; Pasternack A
J Bone Miner Res; 1994 Dec; 9(12):1953-8. PubMed ID: 7872061
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days.
Hanhijärvi H; Elomaa I; Karlsson M; Lauren L
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):602-6. PubMed ID: 2533182
[TBL] [Abstract][Full Text] [Related]
7. Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.
Plosker GL; Goa KL
Drugs; 1994 Jun; 47(6):945-82. PubMed ID: 7521833
[TBL] [Abstract][Full Text] [Related]
8. Comparison of pharmacokinetics of clodronate after single and repeated doses.
Ylitalo P; Holli K; Mönkkönen J; Elo HA; Juhakoski A; Liukko-Sipi S; Ylitalo R
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):294-300. PubMed ID: 10395121
[TBL] [Abstract][Full Text] [Related]
9. Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure.
Hamdy NA; McCloskey EV; Brown CB; Kanis JA
Nephron; 1990; 56(1):6-12. PubMed ID: 2146521
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of clodronate after single intravenous, intramuscular and subcutaneous injections in rats.
Laurén L; Osterman T; Karhi T
Pharmacol Toxicol; 1991 Nov; 69(5):365-8. PubMed ID: 1839447
[TBL] [Abstract][Full Text] [Related]
11. A tolerability and pharmacokinetic study of a new injectable formulation of disodium clodronate in healthy female volunteers.
Poli G; Mariotti F; Corrado ME; Acerbi D
Eur J Drug Metab Pharmacokinet; 2004; 29(2):145-52. PubMed ID: 15230343
[TBL] [Abstract][Full Text] [Related]
12. Steady state pharmacokinetics and dose equivalents of oral clodronate in renal failure.
Mäkelä S; Saha H; Ala-Houhala I; Liukko-Sipi S; Ylitalo P
Int J Clin Pharmacol Ther; 2011 Feb; 49(2):128-36. PubMed ID: 21255529
[TBL] [Abstract][Full Text] [Related]
13. Clodronate in the medical management of hyperparathyroidism.
Hamdy NA; Gray RE; McCloskey E; Galloway J; Rattenbury JM; Brown CB; Kanis JA
Bone; 1987; 8 Suppl 1():S69-77. PubMed ID: 2961358
[TBL] [Abstract][Full Text] [Related]
14. The absolute bioavailability of clodronate from two different oral doses.
Villikka K; Perttunen K; Rosnell J; Ikävalko H; Vaho H; Pylkkänen L
Bone; 2002 Sep; 31(3):418-21. PubMed ID: 12231416
[TBL] [Abstract][Full Text] [Related]
15. Determination of disodium clodronate in human plasma and urine using gas-chromatography-nitrogen-phosphorous detections: validation and application in pharmacokinetic study.
Muntoni E; Canaparo R; Della Pepa C; Serpe L; Casale F; Barbera S; Romano P; Zara GP; Eandi M
J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Jan; 799(1):133-9. PubMed ID: 14659445
[TBL] [Abstract][Full Text] [Related]
16. Elimination of intravenously administered ibandronate in patients on haemodialysis: a monocentre open study.
Bergner R; Dill K; Boerner D; Uppenkamp M
Nephrol Dial Transplant; 2002 Jul; 17(7):1281-5. PubMed ID: 12105253
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of clodronate disodium evaluated in plasma, synovial fluid and urine.
Krueger CR; Mitchell CF; Leise BS; Knych HK
Equine Vet J; 2020 Sep; 52(5):725-732. PubMed ID: 32003488
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing.
Jitmuang A; Nation RL; Koomanachai P; Chen G; Lee HJ; Wasuwattakul S; Sritippayawan S; Li J; Thamlikitkul V; Landersdorfer CB
J Antimicrob Chemother; 2015; 70(6):1804-11. PubMed ID: 25698772
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and tolerability of i.m. disodium clodronate 200 mg/lidocaine 1%, given twice monthly, in comparison with i.m. disodium clodronate 100 mg/lidocaine 1%, given weekly, in healthy postmenopausal female patients.
Radicioni M; Cremonesi G; Baraldi E; Leuratti C; Mariotti F
Int J Clin Pharmacol Ther; 2013 Apr; 51(4):313-22. PubMed ID: 23357844
[TBL] [Abstract][Full Text] [Related]
20. An open-label, non-randomised, phase 1, single-dose study to assess the pharmacokinetics of ceftaroline in patients with end-stage renal disease requiring intermittent haemodialysis.
Sunzel M; Learoyd M; Li J; Li Y; Ngo N; Edeki T
Int J Antimicrob Agents; 2015 Dec; 46(6):682-8. PubMed ID: 26545441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
